Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that ...

It’s not often that researchers get to share encouraging news when it comes to cancer. That’s why the recent announcement ...

Orca-T significantly improved survival free of moderate-to-severe cGvHD compared to alloHSCT, with rates of 78% versus 38%. Orca-T demonstrated a lower incidence of severe acute GvHD and non-relapse ...

Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia treated at specialized cancer centers have significantly higher survival rates than their peers who are not ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of arsenic trioxide (Oral-ATO; ARSENOL) for the treatment of acute promyelocytic ...

MONDAY, May 5, 2025 (HealthDay News) — Testing positive for leukemia actually saved the life of 51-year-old Jan Leahy, a business process owner from Wimbledon, England. Leahy benefitted from a ...